2019 has been an exciting year for Asuragen as we announced the agreement to develop and commercialize companion diagnostics based on our proprietary AmplideX^® PCR technology within the neurodegenerative disease area. In addition, we introduced 3 new Genetics products, launched a substantial update to  our data analysis software, presented numerous scientific posters and continued to host corporate workshops worldwide with key leaders in the healthcare industry. See below for more information on all of our 2019 achievements and activities.

Thank you for your continued support of Asuragen and our journey to provide better answers for people everywhere. We look forward to partnering with you in 2020.

View the press release announcing the partnership: Asuragen-Wave Partnership